What's better than a glass of red wine? Well, my vote would be for two glasses of red wine. However, when you're trying to use a drug that would require a patient to drink 1,000 bottles of wine to get the proper dose, the correct answer is: a more potent drug.
Sirtris plans to get the drugs into clinical trials in the first half of next year, presumably because it's still working on preclinical safety studies.
Sirtris is currently testing SRT501, its proprietary formulation of resveratrol, in combination with metformin, the general version of Bristol-Myers Squibb's
While Sirtris' science is exciting, I'm having trouble getting excited about its valuation. Even with the euphoria around the announcement subsiding, as seen by today's 15% drop in the stock price, the stock still looks a little overpriced for a company with one drug in phase 2 trials. It's going to be a while before Sirtris has a drug on the market, so investors would be well advised to not rush into buying it at these prices. In the meantime, check out other developmental stage drug companies with drugs farther along or companies with diabetes drugs already on the market, such as Amylin Pharmaceuticals
More Foolishness to lower your blood sugar levels:
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Glaxo and Eli Lilly are both selections of the Income Investor newsletter. The Fool has a disclosure policy.